Joshua Silverwood

Whilst Prothena has said that it is still examining the late-stage treatment, the company confirmed it failed to meet its primary endpoint of slowing disease motor progression.

The study found that those treated with a combination of imlifidase and immunoglobulin saw their ability to walk restored in 16 days.

The company announced that it is looking to move to Phase II after its ulcerative colitis treatment saw success over placebo.

As the company quickly swells in size and value, Nvidia has been looking to grow its already large pool of incubated companies with the goal of sustaining the company's massive growth.

The Danish company has announced positive results from its Phase III trial of CagriSema but fell short of a previously promised 25% weight loss.

The Phase III trial is set to use growth outcomes as its primary endpoint in the 52-week trial of JR-142.

Both trials recruited patients with psoriatic arthritis who had not previously received biologic disease-modifying antirheumatic drugs.

The investigational therapy works to impede the expression of genes that cause the body to store fat as a potential treatment for patients living with obesity.

The Texas-based company has said it will investigate the results of its rheumatoid arthritis trial after finding irregularities.

Clinical Trials Arena XBiotech's stock price has taken a hit after it announced a complete halt to its clinical program in rheumatological